Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma

Malignant Pleural Mesothelioma (MPM) is an aggressive tumor that arises from the mesothelial cells of the pleura [1]. It is well established that MPM is almost always caused by professional or non professional exposure to asbestos fibers, while the pathogenetic role of cofactors, such as SV40 viral infection, still remains controversial [2,3]. The average latency period between asbestos exposure and tumor presentation is 30-45 years, depending on duration or intensity of exposure and patient gender [4].

Source: Lung Cancer - July 12, 2019 Category: Cancer & Oncology Authors: Francesco Morra, Francesco Merolla, Debora D ’Abbiero, Gennaro Ilardi, Severo Campione, Roberto Monaco, Gianluca Guggino, Francesca Ambrosio, Stefania Staibano, Aniello Cerrato, Roberta Visconti, Angela Celetti Source Type: research